Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning tablets versus Compound Danshen Tablets for stable exertional angina
ChiCTR2400088437Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Aug 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Guanxinning in stable angina and coronary arteriosclerosis (2 arms), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoint: Change from baseline in Seattle Angina Questionnaire total score at 8 weeks. Started Aug 2024; status: recruiting.
02
Drugs
Guanxinning
03
Conditions
stable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400088437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088437.